Caco-2 Xenograft Model Service for Colon Cancer

The Caco-2 xenograft model is a well-established preclinical platform for evaluating colon cancer therapeutics, offering researchers a reliable system to assess tumor growth dynamics, drug efficacy, and molecular responses in an in vivo setting. Alfa Cytology provides comprehensive Caco-2 xenograft model services tailored to support your colon cancer preclinical research, delivering robust, reproducible data to accelerate your therapeutic development pipeline from early-stage screening to advanced pharmacological evaluation.

Overview of Caco-2 Xenograft Model for Colon Cancer

The Caco-2 cell line was originally established from a human colorectal adenocarcinoma specimen obtained from a 72-year-old Caucasian male patient. Although classified as a colon cancer cell line, Caco-2 cells exhibit unique differentiation properties: upon reaching confluence, they spontaneously differentiate into enterocyte-like cells with well-developed brush borders, tight junctions, and polarized morphology reminiscent of small intestinal absorptive epithelium. This dual nature makes Caco-2 a distinctive model in cancer research, bridging intestinal epithelial biology with colorectal adenocarcinoma studies. The cells express keratin, retinoic acid binding protein I, and retinol binding protein II, and demonstrate increased alkaline phosphatase activity during differentiation. Genetically, Caco-2 cells harbor a TP53 p.Gly245Ala (c.733G>C) mutation in exon 5, which disrupts the protein's phosphorylation recognition motif. Notably, Caco-2 cells are considered to have low tumorigenicity in immunodeficient mice compared to other colorectal cancer cell lines such as HCT116 or HT29, making them particularly valuable for studying differentiated colon cancer phenotypes and drug absorption mechanisms in vivo.

In xenograft applications, Caco-2 models serve as a critical tool for preclinical evaluation of colon cancer therapeutics. The model enables researchers to investigate tumor microenvironment interactions, epithelial barrier integrity, and therapeutic responses in a physiologically relevant context. Studies have demonstrated that Caco-2 xenografts can be utilized to examine the effects of targeted agents on tumor growth, apoptosis induction, and inflammatory signaling pathways. For instance, the lipolysis-stimulated lipoprotein receptor (LSR) has been shown to affect epithelial barrier integrity and tumor xenograft growth in Caco-2 cells, with LSR-deficient tumors exhibiting increased apoptotic and necrotic cell death. Additionally, Caco-2 cells maintain wild-type KRAS and BRAF status, positioning them as a predictive model for EGFR-targeted therapy sensitivity, in contrast to KRAS-mutant or BRAF-mutant lines that confer resistance to anti-EGFR treatments. The model's preserved epithelial characteristics and responsiveness to cytokine-driven inflammation make it suitable for interrogating receptor-level pharmacodynamics and screening agents with selective anti-inflammatory or anti-proliferative potential in colonic epithelial settings.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting colorectal adenocarcinoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving colon cancer progression and epithelial differentiation, and how treatments intersect with these pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment, particularly for EGFR-targeted therapy sensitivity.

Figure 1. Quality control steps for the cultivation of Caco-2 cells on filter inserts. (Hiebl, Verena, et al., 2020)

Cell Line Information: Caco-2

The Caco-2 cell line is a well-established human colorectal adenocarcinoma line with comprehensive molecular characterization. Its unique ability to spontaneously differentiate into enterocyte-like cells with well-developed brush borders and tight junctions makes it unique among available colon cancer cell lines and essential for preclinical research targeting intestinal epithelial biology and drug absorption mechanisms.

Our Services

Alfa Cytology leverages its extensive expertise in preclinical oncology model development to deliver customized Caco-2 xenograft services that align with your specific research objectives. Our integrated platform encompasses cell line authentication, optimized xenograft establishment, comprehensive tumor monitoring, and endpoint analysis, ensuring high-quality, reproducible data to support your colon cancer therapeutic development programs. Whether you require standard subcutaneous xenografts or advanced orthotopic implantation models, our scientific team is equipped to design and execute studies that meet the rigorous demands of modern drug discovery and development.

Workflow of Caco-2 Xenograft Model Construction

The construction of a Caco-2 xenograft model follows a systematic, multi-phase workflow designed to ensure tumor establishment consistency, experimental reproducibility, and data integrity. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Line Authentication and Preparation: Caco-2 cells are authenticated via short tandem repeat (STR) profiling to confirm identity and exclude contamination. Cells are expanded under optimal culture conditions (EMEM + 20% FBS, 37 degrees C, 5% CO2) and harvested at logarithmic growth phase for maximum viability.
2. Cell Viability and Quality Assessment: Harvested cells are assessed for viability (typically >95% via trypan blue exclusion) and resuspended in a suitable carrier matrix such as serum-free medium mixed with Matrigel or PBS to enhance initial engraftment and tumor take rates.
3. Animal Preparation and Ethical Approval: Immunodeficient mice (commonly NOD-SCID, NSG, or nude mice) are acclimatized under pathogen-free conditions. All procedures are conducted under Institutional Animal Care and Use Committee (IACUC) approved protocols with strict adherence to ethical guidelines.
4. Tumor Cell Inoculation: Caco-2 cells (typically 5x10^6 to 1x10^7 cells per mouse) are inoculated subcutaneously into the flank region or orthotopically into the cecal wall, depending on the study design. Inoculation is performed under sterile conditions using a fine-gauge needle to minimize tissue trauma.
5. Tumor Monitoring and Growth Assessment: Tumor growth is monitored by caliper measurement every 2--3 days, with volume calculated using the formula: V = (length x width^2)/2. Tumor take rates and latency periods are recorded to evaluate model consistency.
6. Therapeutic Intervention and Endpoint Analysis: Upon reaching a target tumor volume (typically 100--200 mm^3), mice are randomized into treatment and control groups. Test compounds are administered according to the study protocol (e.g., oral gavage, intraperitoneal, or intravenous injection). Endpoints include tumor growth inhibition rate, survival analysis, histopathological examination (H&E staining), immunohistochemistry (Ki-67, cleaved caspase-3), and molecular profiling (qPCR, Western blot).
7. Data Compilation and Reporting: All experimental data, including tumor growth curves, body weight records, and histological images, are compiled into a comprehensive study report with statistical analysis to support downstream decision-making.

Figure 2: Schematic workflow illustrating the derivation and construction of the Caco-2 Xenograft Model at Alfa Cytology.

Case Study-Caco-2 Xenograft Model Development

In a representative preclinical study, Alfa Cytology established Caco-2 xenografts in immunodeficient mice to evaluate the anti-tumor efficacy of a novel therapeutic candidate targeting colon cancer proliferation pathways. Following successful tumor engraftment and randomization, treatment groups received the investigational compound while control groups received vehicle only. Comprehensive monitoring was conducted throughout the study duration, encompassing tumor volume measurements, body weight tracking, and histopathological analysis at study termination. Preliminary data indicated measurable tumor growth inhibition and favorable tolerability profiles. Detailed quantitative results, statistical analyses, and full histological datasets are available upon request to protect client confidentiality and intellectual property. Please contact our scientific team to discuss specific data points and customize the study design for your research requirements.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific rigor with operational excellence to deliver Caco-2 xenograft model services that meet the highest standards of preclinical research. Our differentiated capabilities ensure reliable, reproducible, and actionable data for your colon cancer therapeutic programs.

• Verified Cell Line Integrity: Expertise in establishing low-tumorigenicity Caco-2 xenografts with optimized protocols for consistent tumor take rates and growth kinetics.
• High Take Rates and Consistency: Comprehensive cell line authentication via STR profiling and mycoplasma testing to guarantee model integrity and data reliability.
• Comprehensive Analytical Support: Flexible study designs accommodating subcutaneous, orthotopic, and patient-derived xenograft (PDX) configurations tailored to your research objectives.
• Tailored Study Designs: Integrated endpoint analysis platform encompassing histopathology, immunohistochemistry, molecular profiling, and pharmacokinetic/pharmacodynamic (PK/PD) correlation.
• Standardized Protocols: Dedicated project management with transparent communication, real-time data access, and timely milestone reporting to keep your program on track.
• Dedicated Project Management: Strict adherence to IACUC guidelines and AAALAC-accredited facilities ensuring ethical, humane, and compliant animal research practices.
• Competitive Timelines: Competitive turnaround times and scalable capacity to support projects ranging from early-stage screening to late-stage IND-enabling studies.

Contact Us

Ready to advance your colon cancer preclinical research with a robust Caco-2 xenograft model? Contact us today to discuss your project requirements, receive a customized study proposal, and explore how Alfa Cytology can accelerate your therapeutic development pipeline. Please reach out to us today via our inquiry form or email to learn more about our Caco-2 Xenograft Model services.

For research use only. Not intended for any clinical use.